NPM1 and Myelodysplasia: The ELN 2022 recommendations suggest that myelodysplasia-related mutations could not offset the favorable impact of NPM1. In this study, all patients with myelodysplasia-related mutations and mutated NPM1 without FLT3-ITD were classified as having a favorable risk.